华邦健康(002004) - 2024 Q4 - 年度业绩预告

Financial Performance Expectations - The company expects a net profit loss ranging from 310 million to 217 million CNY for the fiscal year 2024, a decline of 202.61% to 171.83% compared to the previous year[2][3]. - The net profit after deducting non-recurring gains and losses is projected to be a loss between 350 million and 257 million CNY, representing a decrease of 243.99% to 205.73% year-over-year[2][3]. - Basic earnings per share are anticipated to be a loss between 0.1570 and 0.1099 CNY, compared to a profit of 0.1526 CNY in the previous year[3]. Impairment and Challenges - The company plans to recognize impairment losses on goodwill arising from the acquisition of Baisheng Pharmaceutical due to signs of impairment[5]. - The agricultural chemical new materials segment is facing challenges such as reduced customer demand and intensified market competition, leading to a decline in product prices and gross margins[6]. - The investment income from the agricultural chemical segment has significantly decreased due to the poor performance of major joint ventures in the industry[6]. Financial Reporting - The financial data in the earnings forecast is preliminary and has not been audited, with final figures to be disclosed in the 2024 annual report[7].